Cardiff Oncology, Inc.CRDFNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P15
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -23.15% |
| Q3 2025 | 0.00% |
| Q2 2025 | -100.00% |
| Q1 2025 | 33.31% |
| Q4 2024 | 0.00% |
| Q3 2024 | -100.00% |
| Q2 2024 | 6.18% |
| Q1 2024 | 11.12% |
| Q4 2023 | -7.28% |
| Q3 2023 | -31.59% |
| Q2 2023 | 39.34% |
| Q1 2023 | 0.16% |
| Q4 2022 | 0.03% |
| Q3 2022 | -0.29% |
| Q2 2022 | -21.68% |
| Q1 2022 | 2.74% |
| Q4 2021 | 30.89% |
| Q3 2021 | 3.24% |
| Q2 2021 | 26.98% |
| Q1 2021 | -34.59% |
| Q4 2020 | 107.85% |
| Q3 2020 | -1.50% |
| Q2 2020 | 12.31% |
| Q1 2020 | 154.51% |
| Q4 2019 | -194.63% |
| Q3 2019 | 88.53% |
| Q2 2019 | 3.59% |
| Q1 2019 | -12.46% |
| Q4 2018 | 1.19% |
| Q3 2018 | -22.58% |
| Q2 2018 | -14.14% |
| Q1 2018 | 33.67% |
| Q4 2017 | -54.06% |
| Q3 2017 | -12.72% |
| Q2 2017 | 29.67% |
| Q1 2017 | -23.11% |
| Q4 2016 | -17.05% |
| Q3 2016 | 0.96% |
| Q2 2016 | -20.73% |
| Q1 2016 | 72.28% |